1. Scrip
  2. >>New Products

Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?

 
• By Alaric DeArment

The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.

3D rendering of the Heart valve
Eli Lilly and Boehringer Ingelheim's Jardiance received FDA approval for heart failure with preserved ejection fraction • Source: Shutterstock

The new label expansion for Eli Lilly and Company/Boehringer Ingelheim GmbH’s SGLT2 inhibitor Jardiance (empagliflozin) for heart failure with preserved left ventricular ejection fraction (HFpEF) gives it a significant edge in the space given its superior efficacy and more clearly defined labeling compared with Novartis AG’s heart failure drug Entresto. However, the potential success of another competitor in the SGLT2 inhibitor class could make its reign short-lived.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

More from Scrip